SCHEMBL934644

SCHEMBL934644

FC(F)(F)c1ccc(CBr)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.52
DAO P14920 3/20 0.45
KDM1A O60341 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TKT P29401 1/20 0.40
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PI4KA P42356 1/20 0.36
PIK3CG P48736 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
PDPK1 O15530 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
NAMPT P43490 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30074791 0.84 TRPV4 (0.48) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL28513175 0.84 TRPV4 (0.48) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL991369 0.84 DAO (0.50) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL8927734 0.84 TRPV4 (0.35) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL991269 0.81 DAO (0.48) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL317731 0.79 TRPV4 (0.52) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL452178 0.79 TRPV4 (0.52) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL132198 0.79 TRPV4 (0.52) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL129948 0.79 TRPV4 (0.52) TRPV4DAOKDM1AMAOAMAOB
SCHEMBL456311 0.79 TRPV4 (0.57) TRPV4DAOKDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080069-A Phospholipid compounds and uses thereof 2026-05-26 CN disclosed
EP-4692085-A2 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS Nxera Pharma UK Limited (GB) 2026-02-11 EP disclosed
EP-4041388-B1 PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-11-26 EP disclosed
US-12473314-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-11-18 US disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
EP-4537828-A2 PHOSPHOLIPID COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-04-16 EP disclosed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
EP-4200301-B1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-02-26 EP disclosed
US-20250042889-A1 3CLPRO PROTEASE INHIBITOR SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2025-02-06 US disclosed
US-20240400579-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. 2024-12-05 US disclosed
US-5298507-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1994-03-29 US disclosed
US-5204360-A Insecticides NIHON BAYER AGROCHEM K.K. (JP) 1993-04-20 US disclosed
EP-0212600-B1 NITROMETHYLENE DERIVATIVES NIHON BAYER AGROCHEM K.K. (JP) 1991-11-27 EP disclosed
US-5001138-A Insecticides NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) 1991-03-19 US disclosed
US-4845106-A INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-07-04 US disclosed
US-4812454-A Nitromethylene derivatives and their use as insecticides NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-03-14 US disclosed
US-4772620-A MITICIDES, PARASITICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1988-09-20 US disclosed
US-4742060-A 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1988-05-03 US disclosed
EP-0212600-A2 Nitromethylene derivatives NIHON BAYER AGROCHEM K.K. (JP) 1987-03-04 EP disclosed
EP-0192060-A1 Heterocyclic compounds NIHON BAYER AGROCHEM K.K. (JP) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400579-A1 SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION MAG, NR1H2, PMP22 TRPV4 3784/4885DAO 4549/4885KDM1A 2800/4885
US-20250042889-A1 3CLPRO PROTEASE INHIBITOR ACE, ACE2, CTRL TRPV4 4372/4885DAO 1089/4885KDM1A 795/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 TRPV4 2033/4885DAO 1249/4885KDM1A 1279/4885
US-12473314-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 TRPV4 2452/4885DAO 2393/4885KDM1A 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.